SCHEMBL2825944

SCHEMBL2825944

CSc1ccc(Cn2cc(COC(=O)c3ccc(OC(C)(C)C(=O)OC(C)(C)C)cc3)cn2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.35
MAPT P10636 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
KDM4E B2RXH2 3/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
HTT P42858 1/20 0.35
HDAC3 O15379 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
NCOR2 Q9Y618 1/20 0.34
KLKB1 P03952 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
HSD17B10 Q99714 1/20 0.34
CYP1A2 P05177 2/20 0.33
CYP3A4 P08684 2/20 0.33
RHEB Q15382 1/20 0.33
PLA2G1B P04054 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2819374 0.90 TBXAS1 (0.42) L3MBTL1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL2821944 0.89 LMNA (0.42) L3MBTL1MAPTRAB9AKMT2AHSD17B10
SCHEMBL2819390 0.88 THRB (0.38) L3MBTL1MAPTNPC1RAB9AKLKB1
SCHEMBL2823014 0.85 KLKB1 (0.39) MAPTSMN1; SMN2KLKB1MEN1KMT2A
SCHEMBL2819683 0.85 KLKB1 (0.37) L3MBTL1MAPTSMN1; SMN2RAB9AKLKB1
SCHEMBL2822731 0.82 RARA (0.36) MAPTSMN1; SMN2KLKB1CYP1A2CYP3A4
SCHEMBL2824753 0.81 TBXAS1 (0.43) L3MBTL1MAPTSMN1; SMN2KDM4ENPC1
SCHEMBL2819508 0.80 TSHR (0.36) L3MBTL1MAPTKDM4ENPC1RAB9A
SCHEMBL2819470 0.79 L3MBTL1 (0.47) L3MBTL1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL2822380 0.79 LMNA (0.41) L3MBTL1MAPTRAB9AKMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100184815-A1 AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC 2010-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184815-A1 AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA PPARA, PPARD, PPARG L3MBTL1 4855/4885MAPT 4229/4885SMN1; SMN2 4788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.